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ABSTRACT
Intranasal drug delivery is becoming an increasingly important form of drug administration for
chronic and chronic-intermittent diseases. Important new applications currently in development
include drugs for diabetes, osteoporosis, obesity, certain types of convulsive disorders, migraine
headaches, symptomatic pain relief, nausea, and anxiety, among others. Transmucosal absorption
across the nasal mucosa is generally limited to molecules less than 1,000 Da. Systemic delivery of
larger molecules requires formulations with a suitable transmucosal absorption enhancer. More than
one hundred potential transmucosal absorption enhancing excipients have been tested to date.
Nearly all have failed due to poor effectiveness or unacceptable toxicity to the mucosal tissue.
Alkylsaccharides, cyclodextrins, and chitosans have emerged as leading candidates for potential
broad clinical applications allowing the development of convenient, patient-friendly, needle free
formulations of small molecule drugs, as well as, peptide and protein drugs that can be administered
at home, at work, or in other public and private settings outside of the doctor’s office or hospital
environment.  
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INTRODUCTION
Intranasal drug delivery continues to evolve as
an important form of drug delivery. The key
aspects driving the growing adoption of nasal
delivery include rapid drug absorption
compared to subcutaneous injection or oral
administration, the avoidance of hepatic first
pass effect, greater patient convenience and
compliance, and the elimination of needle stick
injuries and bio hazardous waste disposal
problems associated with the use of syringes. In
addition, consumer demographic trends point
to an increasing popularity of self-
administration of drugs for personal
management and the control of chronic
diseases. Topical nasal applications such as
therapies for nasal congestion and allergic
rhinitis still account for the major share of* Corresponding author: Edward T. Maggio, PhD, Aegis Therapeutics
LLC, San Diego, CA USA, E-mail: emaggio@aegisthera.com
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intranasal drug delivery. However, nasal
administration of drugs intended for systemic
absorption in the treatment of chronic diseases
such as diabetes, osteoporosis, obesity, certain
types of convulsive disorders, migraine
headaches, together with symptomatic relief of
pain, nausea, and anxiety is rapidly growing.
The US market alone for intranasal drug
delivery is projected to reach US $4.4 billion by
the year 2015.
ADVANTAGES OF INTRANASAL DELIVERY
AND SOME EXAMPLES
Nasal delivery is suitable for the treatment of
chronic conditions such as diabetes,
osteoporosis, obesity, as well as, chronic-
intermittent conditions such as migraine or
breakthrough seizures. In general, intranasal
delivery provides a convenient, patient-friendly,
nonthreatening, needle free, pain free,
administration route allowing for self-
administration at home, at work, or in other
public settings. As an example of improved
convenience, at present the only approved out-
of-hospital treatment for breakthrough seizures,
in the US, is a diazepam rectal gel (Diastat®).
Because of its inconvenient administration
route it is prescribed essentially only for infants
or very young children. Affected adults must
wait for emergency treatment to arrive,
transportation to hospital, intravenous
administration of diazepam together with an
overnight observational stay at a total cost of
approximately US $3,000, or more. A novel
formulation, developed by San Diego-based
Neurelis Corporation, incorporating a highly
effective absorption enhancer has allowed the
otherwise poorly nasally absorbed diazepam to
be delivered with 96% absolute systemic
bioavailability (1). As a replacement for rectal
gel, it allows immediate treatment on-site and
provides an excellent illustration of the
importance of nasal delivery as a convenient
alternate delivery mode.  
An example of the benefit of increased speed
of systemic absorption that can be achieve
through nasal delivery is shown in Figure 1.
Figure 1 shows a comparison of the
pharmacokinetics of nasal administration of
sumatriptan containing the specific absorption
enhancer dodecyl maltoside (DDM) with nasal
administration of the same dose of sumatriptan
in the absence of DDM. The Tmax of nasally
administered sumatriptan in the presence of the
absorption enhancer is approximately 8 minutes
compared to approximately 60-120 minutes for
the currently available nasally administered
sumatriptan. The DDM-enhanced nasal
formulation reaches an equivalent therapeutic
blood level in only 2-3 minutes, approximately
20-30 times faster than currently commercially
available oral or nasal products (2).
Intranasal delivery can the speed absorption of
much larger, otherwise injectable-only peptide
drugs, as well. For peptides or proteins such as
insulin, leptin, or growth hormone the Tmax
values for nasal administration have been
shown to be one half or less of the
corresponding Tmax values for injections of
these same proteins (3, 4).
Avoiding the hepatic first-pass metabolism
effect is another advantage of systemic nasal
delivery. Bypassing the GI tract allows more
reliable and reproducible bioavailability to be
achieved. Drugs that undergo extensive first-
pass metabolism, display erratic absorption, or
require quick therapeutic onset are potentially
good drug candidates for intranasal delivery,
particularly those that would otherwise require
an injection. 
NASAL ANATOMY, PHYSIOLOGY, AND
ABSORPTION PROCESSES
The nose is divided into two nasal cavities by
the septum, each with a volume of
approximately 7.5 ml and a surface area of
approximately 75 cm2 (5, 6). Of the three
distinct functional regions in the nose, namely,
the vestibular, respiratory, and olfactory
regions, the respiratory region is the largest and
comprises approximately 65 cm2. It is highly
vascularized and is the principal site of systemic
drug absorption (6). The respiratory epithelium
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Figure 1 The absorption enhancement effect of DDM on the plasma profile of nasally
administered sumatriptan in humans (mean ± S.D.). Tmax  is reduced from 60-120 for the
currently marketed nasal or oral sumatriptan down to 8 minutes with equivalent therapeutic
levels achieved at 2 minutes, and the bioavailability as measured by the AUC (area under the
curve) is significantly increased.
consists of basal cells, mucus-containing goblet
cells, ciliated columnar cells, and non-ciliated
columnar cells (5, 6). The cilia are surrounded
by a film of mucus and move in a continuous
wavelike fashion to transport mucus and
entrapped particles to the pharynx for ingestion
(6 - 8). 
Mucus is a viscous colloid comprised of mucins
(glycoproteins that are produced by goblet cells
in the mucous membranes and submucosal
glands), together with antibacterial proteins
such as lysozyme and lactoferr in,
immunoglobulins, and inorganic salts (9). The
constantly regenerating mucus coating moves at
5 to 6 mm/min. (5, 10) and serves to protect
epithelial cells from external insults (viruses,
bacteria, and chemical irritants). By restricting
drop size in nasally administered sprays to a
diameter >10 µm deposition is restricted to the
nasal cavity and lung exposure is essentially
zero (11-14). The pH range of the nasal cavity
is approximately 5.5 to 6.5 so nasal irritation is
minimized when products are formulated
within this pH range (15, 16). The total spray
volume that can be reliably delivered to each
naris is limited by the size of the nasal cavity
and generally thought to be no more than
150 μl and the upper limit of a drug dose has
been suggested to be 25 mg/dose (16). 
ABSORPTION ENHANCING EXCIPIENTS
There are two primary mechanisms for
absorption through the mucosa. They are
paracellular transport via opening of tight
junctions between cells, and transcellular
transport or transcytosis through cells via
vesicle carriers (3, 17). Obstacles to drug
absorption are potential metabolism before
reaching the systemic circulation and, limited
residence time in the cavity. Some transmucosal
absorption enhancers function by altering either
or both the paracellular and transcellular
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pathways, while others serve to extend
residence time in the nasal cavity or prevent
metabolic changes, e.g., unwanted peptide
hydrolysis. 
Dozens of excipients have been tested as
potential enhancers of intranasal absorption
over the course of the last three decades in the
hope that alternate noninvasive means of
administering peptides, proteins, and small
molecule drugs might be achieved. Table 1 lists
some of these. Nearly all of the molecules
tested to date have been shown to cause
significant and, in some cases, serious damage
to the nasal mucosa upon repeated
administration, especially at concentrations high
enough to achieve a substantial degree of
transmucosal absorption enhancement. Indeed,
the principal factors limiting broad acceptance
of intranasal administration have been damage
to the nasal mucosa coupled with poor
transmucosal absorption caused by the
absorption enhancers. The few exceptions,
which include the alkylsaccharides,
cyclodextrins, and chitosans, are among the
most effective and are generally well tolerated,
with varying degrees of effectiveness as
absorption enhancers. 
In the absence of an absorption enhancer, the
apparent molecular weight cut-off point for
nasal absorption is approximately 1,000 Da,
with molecules less than 1,000 Da having better
absorption (43). Co-administration of drugs
with absorption enhancers promotes the
absorption of drugs ranging in size from 1,000
Da to 31,000 Da. The principle mechanisms for
increased absorption are loosening of tight
junctions between cells, enhanced vesicular
transcytotic transport, alteration of the
rheological (fluidity) properties of the mucus
and/or alteration of the cilia (i.e., paralysis of
ciliary beating or removal of cilia from the
epithelial cells that line the nasal cavity (3, 23,
44-52). The latter two mechanisms serve to
increase the residence time of drug in the nasal
cavity allowing more time for passive diffusion.
Table 1 Some examples of molecules that have been
used as transmucosal absorption enhancers. Excipients
used in human trials are shown in bold. Of these,
excipients exhibiting no reported irritation are marked













Glycocholic acid, sodium salt (25)


















Salicylic acid, sodium salt (20)
β-Sitosterol- β-D-glucoside (38)
Sucrose cocoate (39)
Taurocholic acid, sodium salt (40)
Taurodeoxycholic acid, sodium salt (41)
Taurodihydrofusidic acid, sodium salt (42)
Tetradecyl maltoside (2)
TOXICITY ASSESSMENT
Two principal requirements for useful
absorption enhancers are significant
effectiveness and safety. Extensive in vivo
studies aimed at assessing the effectiveness and
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toxicity of more than 50 possible absorption
enhancers were conducted by Chen et al. (22)
using the measurement of transepithelial
electrical resistance across confluent cell layers
c o m p r i s e d  o f  c u l t u r e d  h u m a n
bronchial/tracheal epithelial cells in a microtiter
well format. If exposure to the cells by one of
the 50, or so, test excipients resulted in a
reduction in transepithelial electrical resistance
(TEER) across the confluent cell layer, it was
interpreted as an opening of tight junctions
between the cells. Similar studies have been
repeated by Vllasaliu et al. using Calu-3 cells
(53). The reduction in TEER in vitro seems to
correlate with potential  absorption
enhancement properties in vivo though the
correlation is not by any means perfect.
Attempts to use this same cell based model for
toxicity assessment is not predictive because of
gross difference between the in vitro and in situ
cell environments. In vitro cell culture models of
nasal mucosa are understandably deficient from
a number of perspectives. Some of these
deficiencies apply in general to assessment of all
excipients and some are deficiencies specific to
the particular excipient being tested. From a
general deficiency perspective, both studies
exposed the naked confluent cells in culture
media to excipients for 60 to 120 minutes at
37°C. During this time, the naked cells were
continuously exposed to continuous high
concentrations of the excipient. 
In contrast, in the nasal cavity, the epithelial
cells lining the nasal cavity are bathed in a
constantly regenerating mucus coating that
flows at a rate of 5 - 6 mm/min. resulting in a
mucocilliary clearance time of approximately 15
minutes. Thus the contact time of exposure of
nasal epithelia, and the concentration of both
excipient and drug is progressively and
continuously reduced by three means i.e.,
dilution into the mucus, absorption into the
systemic circulation, and physical removal
through the mucocilliary clearance mechanism.
Assuming a linear concentration reduction over
15 minutes the integrated exposure (i.e., time X
concentration) to excipient is lower by a factor
of 8- to 16-fold in the physiological
circumstance compared to the 60 to 120-
minute incubation times, respectively, for the
naked cells. Further, the intrinsic properties of
mucus whose complex composition of mucin
glycoproteins, lysozyme, lactoferrin, and
immunoglobulins, is precisely designed as a
natural protection against external insults
cannot be factored into the in vitro cell assay. 
ALKYLSACCHARIDES
Alkylglycosides and sucrose esters of fatty acids
are nonionic alkylsaccharide surfactants that
consist of an aliphatic hydrocarbon chain
coupled to a sugar moiety by a glycosidic or
ester bond, respectively. The particular
alkylsaccharides that were shown to be effective
absorption enhancers are odorless, tasteless,
non-toxic, non-irritating, non-mutagenic, and
non-sensitizing in the Draize test at
concentrations of up to 25% (54, 55). They are
synthesized as single chemical entities
composed of a sugar, typically a disaccharide,
and an alkyl chain, typically 10 to 16 carbon
atoms in length. They provide controlled
transient permeation of the nasal mucosal
barrier with no irritation. Following absorption
or ingestion they metabolize to CO2 and H2O
through the corresponding sugar and fatty acid
(56, 57).
Alkylglycosides are widely used in the food
industry. For example, they are sprayed on
fruits and vegetables to prevent the growth of
bacteria and fungi or, used to clean food
processing equipment, primarily because of
their intrinsic and highly effective antimicrobial
activity and lack of toxicity. The EPA has
determined that there is no need to establish an
upper limit of exposure for adults, children or
infants (58).
Similarly, sucrose esters find widespread use as
food-grade emulsifiers and in cosmetic
preparations. The No Observed Effect Level
(NOEL) for these molecules is as high as 2,000
mg/kg body weight in some instances (56) and
are designated as Generally Recognized As Safe
(GRAS) substances for food applications. They
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are used in such small amounts that the WHO
oral allowable daily intake (ADI) is nearly
10,000 times (56) the amount that would be
used in a typical single nasal spray dose (i.e.,
200 µg/spray versus 2 g/day ADI).
Despite the accumulation of considerable
experimental evidence concerning the efficacy
of alkylglycosides as absorption-enhancers,
their mechanism of action remains unknown.
Alkyl maltosides appear to enhance
transmucosal delivery of peptides through
transcellular, and paracellular, pathways (3, 59).
Transmission electron micrographs of the nasal
septa of rats show, immediately after the
exposure to alkyl maltoside, unstained regions
that are consistent with cellular internalizations
and areas of thinned cilia associated with vesicle
formation (3). The transcellular pathway is
further supported by fluorescence light
micrographs showing the internalization of
fluorescein-labeled insulin administered
intranasally with an alkyl maltoside (3). As
stated above, the paracellular pathway is
nominally demonstrated by a decrease in the
transepithelial electrical resistance (TEER) and
an increase in mannitol movement across a
confluent layer of human bronchial epithelial
cells in the presence of tetradecyl maltoside
(36).
Studies have shown that alkylglycosides and
sucrose esters are among the most effective
nasal absorption enhancers for a wide range of
pept ide ,  prote in ,  and non-pept ide
macromolecular drugs in rats, mice, cats, dogs
and monkeys (60-66). Dose-escalation studies
were conducted in rats to determine the
potencies of various alkylglycosides and sucrose
esters in increasing nasal absorption of insulin
and to determine the contribution of the
alkylchain and the sugar moiety. These studies
revealed that shorter chained alkylsaccharides
coupled to glucose, such as hexyl, heptyl, octyl
or nonyl glucoses, were ineffective, or
minimally effective, at promoting insulin
absorption from the nose (63, 65).
Intermediate-length alkylsaccharides such as
decanoyl sucrose, decyl maltoside, or octyl
maltoside were more effective in promoting
nasal insulin absorption. Longer chain
alkylsaccharides such as dodecyl maltoside,
tridecyl maltoside, tetradecyl maltoside, and
sucrose dodecanoate were very potent
absorption enhancers, even at concentrations as
low as 0.03-0.06%. No other absorption-
enhancing agents tested to date have been as
effective at such low concentrations.
Interestingly, increasing the alkyl chain length
beyond 14 carbons (e.g., pentadecyl maltoside,
or hexadecyl maltoside) decreases the potency
of nasal insulin absorption. 
CYCLODEXTRINS
Cyclodextrins (CD) are cyclic oligosaccharides
composed of six or more monosaccharide units
with a central cavity. Cyclodextrins can form
inclusion complexes with hydrophobic
molecules and they have primarily been used to
increase drug solubility and dissolution and to
enhance low molecular weight drug absorption
(67, 68). Among the cyclodextrin derivatives
studied as potential nasal insulin absorption
enhancers, dimethyl-beta-cyclodextrin was
found to be the most effective, while alpha-CD
was less effective and beta- and gamma-CD had
negligible effects on insulin absorption (69).
Cyclodextrins are believed to interact with
cholesterol within the cell membrane (70). This
interaction transiently opens tight junctions
which may explain their ability to facilitate
peptide absorption across the nasal mucosa
(49). Since not all cyclodextrins are effective at
increasing peptide bioavailability, the
architecture of the central cavity appears to be
critical for nasal peptide drug absorption.
Previous work has demonstrated that dimethyl-
beta-cyclodextrin was effective in promoting
the absorption of a number of drugs including
insulin (72, 73), calcitonin (40), and low
molecular weight heparin (74). Gamma
cyclodextrin is ineffective at increasing peptide
drug absorption. 
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CHITOSAN
Chitosan is a linear cationic polysaccharide
produced from the deacetylation of chitin, a
component of the shells of shrimp and other
crustaceans (7, 79, 80). Chitin is composed of
randomly distributed β-(1-4)-linked D-
glucosamine and N-acetyl-D-glucosamine
joined by glycosidic bonds.
Chitosan has been shown to increase the
bioavailability of insulin and other small
peptides and polar macromolecules in different
animal models (75-77). Chitosan exhibits
bioadhesive properties and interacts strongly
with nasal mucus layer enhancing the contact
time for drug with membrane. The addition of
0.2-0.5% chitosan to nasal formulations of
insulin resulted in significant increases in
plasma insulin and reductions in blood glucose
in both sheep and rat models. Studies in human
volunteers demonstrated that nasal
administration of chitosan formulations results
in significantly longer nasal clearance times (78)
suggesting that chitosan decreases mucociliary
clearance and prolongs the residence time of
peptides within the nasal cavity (79-86).
Chitosan also produces a transient opening of
tight junctions of confluent Caco-2 cells (87). 
BILE SALTS AND DERIVATIVES
Attempts to administer insulin non-invasively
through the nasal route using bile salts date
back nearly three decades (42) with mixed
results. Bile salts and their derivatives, such as
sodium glycocholate, sodium taurocholate, and
sodium taurodihydrofusidate, were shown to
effectively promote nasal insulin absorption
(41, 45, 88, 89) and were subsequently
extensively studied for their ability to promote
the absorption of a variety of peptide drugs
from several alternative delivery sites (90, 91).
The mechanisms of action by which the bile
salts/derivatives promote increased nasal
absorption of peptide drugs are not well
understood. Possible explanations may include
the fluidization of the nasal epithelial cell
membranes, increases in transcytotic movement
of peptides via endocytotic vesicles, or the
inhibition of certain proteolytic enzymes
capable of degrading peptides before they can
successfully cross the nasal epithelium.
Inclusion of sodium glycholate in an insulin
formulation resulted in a significant reduction
in enzymatic degradation of insulin (92).
Through circular dichroism and alpha-
chymotrypic degradation studies, a dose-
response relationship between increasing
concentrations of sodium glycholate and the
presence of monomeric insulin has been shown
(92). Similarly, sodium taurocholate has been
shown to increase disaggregation of insulin
hexamers in a dose dependent manner (92).
Unfortunately, in test subjects bile salts and
derivatives were found to produce significant
nasal irritation, stinging and lacrimation. So
while early attempts to administer insulin using
bile salt-based formulations successfully
achieved useful systemic blood levels and a
corresponding reduction in blood glucose
levels, the resulting nasal damage was
unacceptable and not tolerated by test subjects.
This experience with the bile salt excipients
illustrates the most significant challenge for the
practical broad adoption of nasal drug delivery. 
COMPARATIVE STUDIES
The three types of absorption enhancers that
have been studied most extensively, namely
alkylsaccharides, cyclodextrins, and chitosan,
have proven useful for nasal delivery of small
molecule drugs, as well as, for peptide and
protein drugs. Each offers potential advantages
over the others in specific applications. For
example, chitosan has proven useful as an
absorption enhancer for both aqueous solution
and dry powder formats. Cyclodextrins have
been used in aqueous solutions where they not
only increase transmucosal absorption, but can
also increase solubility of hydrophobic drugs.
Alkylsaccharides, which provide the greatest
degree of absorption enhancement in most
applications, are soluble in aqueous and oil-
based/organic liquid formulations and are
being used in both formats. In addition,
alkylsaccharides prevent peptide and protein 
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Figure 2 Single dose pharmacokinetics study of
intranasally administered GLP-1 analog in Sprague Dawley
rats.  Data courtesy of QED Bioscience Inc.,  San Diego,
CA.








Intravenous calcitonin control none 100% 10 IU/KG
(28)
Nasal calcitonin, in pH 4 isotonic phosphate buffer 1% chitosan free amine 2.45% 10 IU/KG
Nasal calcitonin, in pH 4 isotonic phosphate buffer 5% dimethyl-beta-
cyclodextrin
1.91% 10 IU/KG
Nasal calcitonin in pH 4 isotonic phosphate buffer
control
None 1.22% 10 IU/KG
Nasal calcitonin in pH 3.75, 6 mM sodium acetate,
0.9% sodium chloride
0.125% tetradecyl maltoside 52% 8 IU/KG (66)
aggregation (93, 94). There are few direct
comparative studies assessing differences in
absorption enhancement efficiency in the
literature. Published studies on the nasal
bioavailability of calcitonin, a peptide drug 32
amino acids in length with an approximate
molecular weight of 3,500 Da (66, 93) provides
one such example. Sinswat et al. (28) compared
the absolute bioavailability of calcitonin
administered nasally to rats using cyclodextrins
and chitosan’s as the absorption enhancers to
intravenous calcitonin as the control. Ahsan et
al. carried out a similar study, again in rats,
using alkylsaccharide tetradecylmaltoside as the
absorption enhancer, again using intravenous
administration as the control (66). The results
are shown in Table 2.
In these side by side comparisons, the
formulation containing the alkylsaccharide
excipient tetradecyl maltoside was found to be
significantly more effective than either of the
formulations containing chitosan or dimethyl
beta cyclodextrin.
Data from a study comparing intranasal
absorption of a GLP-1 analog oligopeptide in
Sprague Dawley rats are shown in Figure 2. In
this study, two alkylsaccharides, dodecyl
maltoside (DDM) and sucrose dodecanoate
(SDD) were compared to the bile acid
absorption enhancer sodium taurocholate,
together with Tween 20 (polysorbate-20) and
phosphate buffered saline as a negative control.
Rats were anesthetized using isoflurane/O2
mixture and dosed with 40 µg of the GLP-1
analog by instillation of a 20 µl drop into a
single naris. Solutions of the GLP-1 analog and
excipient (DDM, SDD, sodium taurocholate,
Tween-20) were prepared in 20 mM phosphate
buffer, pH 7.0. Each group of 12 rats was
matched by body weight. Blood samples were
drawn at the timed intervals shown and
assayed.
The molecular weight of GLP-1 at 4,112 Da is
slightly larger than calcitonin, but very much
within the molecular weight range suitable for
intranasal peptide administration. Of the two
alkylsaccharides tested, dodecyl maltoside
appeared to be better than sucrose dodecanoate
and both were superior to sodium taurocholate.
The polysorbate surfactant Tween-20 exhibited
no absorption enhancement and was
comparable to the phosphate buffer control.
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CONCLUSION
More than one hundred potential transmucosal
absorption enhancing excipients have been
tested to date. Nearly all failed due to poor
effectiveness or unacceptable toxicity to
mucosal tissue. Alkylsaccharides, cyclodextrins,
and chitosan’s have emerged as the leading
candidates for potential broad clinical
applications. Certain molecules from all three
types are able to exert their desired effects
without causing transmucosal damage and all
three have demonstrated clinical utility in
human studies together with demonstrated
safety and lack of intranasal toxicity. A principal
mechanistic benefit shared by these absorption
enhancing excipients is the fact that they
function independently of the drug, that is, they
act on the transmucosal membranes and do not
require a modification of the drug substance. 
It is certainly desirable that additional research
is carried out to identify better alternatives. In
undertaking such research there are two
impediments that must be overcome. First,
there is a practical limit to the size of molecules
that can be absorbed transmucosally. A
practical molecular weight limit is estimated to
be in the range of approximately 25 – 30 kDa.
This is because there is a physical limit to the
extent to which tight junctions can be opened
without tissue damage. Absorption by the
transcellular route is not subject to similar size
limitation and may even allow absorption of
nanoparticles, well beyond the size of soluble
peptide or protein molecules (95). It is possible
that a combination of excipients which
separately maximize paracellular and
transcellular absorption could be worth
pursuing. Nevertheless, it may be difficult to
develop alternative excipients that exceed the
performance of those tested to date without
causing unacceptable tissue damage.
A second impediment and practical “real
world” concern relates to the regulatory
requirement to assess the potential for toxicity
before being permitted to conduct human
clinical trials. In every case, care must be taken
to fully assess the potential for toxicity upon
chronic administration of novel excipients.
Today, literally thousands of patients have been
exposed to intranasal administration of drugs
using alkylsaccharides, cyclodextrins, and
chitosan’s and thus there is a growing database
of safety experience with these excipients.
Because of the ever-increasing cost of
preclinical, as well as, clinical studies the cost to
duplicate this experience base in itself has
become somewhat of a significant impediment.
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